You are here

  • Home
  • Online First
  • HLA-DRB1*0901 lowers anti-cyclic citrullinated peptide antibody levels in Japanese patients with rheumatoid arthritis

Article Text

Article menu

other Versions

Download PDFPDF
Letter
HLA-DRB1*0901 lowers anti-cyclic citrullinated peptide antibody levels in Japanese patients with rheumatoid arthritis
  1. Yukinori Okada1,*,
  2. Akari Suzuki2,
  3. Ryo Yamada3,
  4. Yuta Kochi2,
  5. Kenichi Shimane2,
  6. Keiko Myouzen2,
  7. Michiaki Kubo2,
  8. Yusuke Nakamura3,
  9. Kazuhiko Yamamoto1
  1. 1 The University of Tokyo, Japan;
  2. 2 Institute of Physical and Chemical Research (RIKEN), Japan;
  3. 3 Institute of Medical Science, the University of Tokyo, Japan
  1. Correspondence to: Yukinori Okada, Department of Allergy and Rheumatology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan; yokada-tky{at}umin.ac.jp

Abstract

Anti-cyclic citrullinated peptide (anti-CCP) antibody is a highly specific biomarker for Rheumatoid Arthritis (RA), and recognized as a predictor of development of RA.[1,2] It had been demonstrated that some HLA-DRB1 alleles, such as shared epitope (SE) alleles, significantly contribute to the positivity of anti-CCP antibody and the susceptibility of anti-CCP antibody-positive RA.[3,4] However, the quantitative effect of HLA-DRB1 alleles on anti-CCP antibody levels in RA patients is controversial.[3,5,6] Therefore, we carried out a large-scale study to study the quantitative effects of HLA-DRB1 alleles on anti-CCP antibody levels in Japanese patients with RA.

https://doi.org/10.1136/ard.2009.118018

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes